Literature DB >> 21540555

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Katelyn T Byrne1, Anik L Côté, Peisheng Zhang, Shannon M Steinberg, Yanxia Guo, Rameeza Allie, Weijun Zhang, Marc S Ernstoff, Edward J Usherwood, Mary Jo Turk.   

Abstract

A link between autoimmunity and improved antitumor immunity has long been recognized, although the exact mechanistic relationship between these two phenomena remains unclear. In the present study we have found that vitiligo, the autoimmune destruction of melanocytes, generates self antigen required for mounting persistent and protective memory CD8+ T cell responses to melanoma. Vitiligo developed in approximately 60% of mice that were depleted of regulatory CD4+ T cells and then subjected to surgical excision of large established B16 melanomas. Mice with vitiligo generated 10-fold larger populations of CD8+ memory T cells specific for shared melanoma/melanocyte antigens. CD8+ T cells in mice with vitiligo acquired phenotypic and functional characteristics of effector memory, suggesting that they were supported by ongoing antigen stimulation. Such responses were not generated in melanocyte-deficient mice, indicating a requirement for melanocyte destruction in maintaining CD8+ T cell immunity to melanoma. Vitiligo-associated memory CD8+ T cells provided durable tumor protection, were capable of mounting a rapid recall response to melanoma, and did not demonstrate phenotypic or functional signs of exhaustion even after many months of exposure to antigen. This work establishes melanocyte destruction as a key determinant of lasting melanoma-reactive immune responses, thus illustrating that immune-mediated destruction of normal tissues can perpetuate adaptive immune responses to cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21540555      PMCID: PMC3083789          DOI: 10.1172/JCI44849

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.

Authors:  F A Le Gal; M F Avril; J Bosq; P Lefebvre; J C Deschemin; M Andrieu; M X Dore; J G Guillet
Journal:  J Invest Dermatol       Date:  2001-12       Impact factor: 8.551

2.  The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.

Authors:  Annemieke Th den Boer; Geertje J D van Mierlo; Marieke F Fransen; Cornelis J M Melief; Rienk Offringa; René E M Toes
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Perilesional leucoderma in metastatic melanoma. The use of the Wood's light for early detection of this rare reaction.

Authors:  L Goldman; R G Wilson; R Glasgow; R Richfield
Journal:  Acta Derm Venereol       Date:  1967       Impact factor: 4.437

5.  Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.

Authors:  Renée Lengagne; Frédérique-Anne Le Gal; Marylène Garcette; Laurence Fiette; Patrick Ave; Masashi Kato; Jean-Paul Briand; Christian Massot; Izumi Nakashima; Laurent Rénia; Jean-Gérard Guillet; Armelle Prévost-Blondel
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

6.  GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines.

Authors:  Miguel-Angel Perales; Giamila Fantuzzi; Stacie M Goldberg; Mary Jo Turk; Fariborz Mortazavi; Klaus Busam; Alan N Houghton; Charles A Dinarello; Jedd D Wolchok
Journal:  Cytokines Cell Mol Ther       Date:  2002

7.  A simple method to cure established tumors by inflammatory killing of normal cells.

Authors:  Gregory A Daniels; Luis Sanchez-Perez; Rosa Maria Diaz; Timothy Kottke; Jill Thompson; Maoyi Lai; Michael Gough; Mahzuz Karim; Andrew Bushell; Heung Chong; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Nat Biotechnol       Date:  2004-08-01       Impact factor: 54.908

8.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

9.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779

10.  Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Authors:  Mary Jo Turk; José A Guevara-Patiño; Gabrielle A Rizzuto; Manuel E Engelhorn; Shimon Sakaguchi; Alan N Houghton
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

View more
  32 in total

1.  Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

Authors:  Maria Muccioli; Caitlin Longstaff; Fabian Benencia
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

2.  Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

Authors:  David C Binder; Boris Engels; Ainhoa Arina; Ping Yu; James M Slauch; Yang-Xin Fu; Theodore Karrison; Byron Burnette; Christian Idel; Ming Zhao; Robert M Hoffman; David H Munn; Donald A Rowley; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2013-08       Impact factor: 11.151

3.  Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Authors:  Katelyn T Byrne; Peisheng Zhang; Shannon M Steinberg; Mary Jo Turk
Journal:  J Immunol       Date:  2014-01-08       Impact factor: 5.422

4.  Resident memory T cells in the skin mediate durable immunity to melanoma.

Authors:  Brian T Malik; Katelyn T Byrne; Jennifer L Vella; Peisheng Zhang; Tamer B Shabaneh; Shannon M Steinberg; Aleksey K Molodtsov; Jacob S Bowers; Christina V Angeles; Chrystal M Paulos; Yina H Huang; Mary Jo Turk
Journal:  Sci Immunol       Date:  2017-04-14

5.  CD70 and Th17 are involved in human contact sensitivity.

Authors:  David S Lee; Nicholas Gulati; Frank Martiniuk; William R Levis
Journal:  J Drugs Dermatol       Date:  2011-10       Impact factor: 2.114

Review 6.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.

Authors:  Alexis L Franks; Jill E Slansky
Journal:  Anticancer Res       Date:  2012-04       Impact factor: 2.480

7.  Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Authors:  Jason R Baird; Katelyn T Byrne; Patrick H Lizotte; Seiko Toraya-Brown; Uciane K Scarlett; Matthew P Alexander; Mee Rie Sheen; Barbara A Fox; David J Bzik; Marcus Bosenberg; David W Mullins; Mary Jo Turk; Steven Fiering
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

8.  Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.

Authors:  Arnaud Pommier; Alexandra Audemard; Aurélie Durand; Renée Lengagne; Arnaud Delpoux; Bruno Martin; Laetitia Douguet; Armelle Le Campion; Masashi Kato; Marie-Françoise Avril; Cédric Auffray; Bruno Lucas; Armelle Prévost-Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

9.  Combination immunotherapy for high-risk resected and metastatic melanoma patients.

Authors:  Adam I Riker; Gabriela R Rossi; Prerna Masih; L C Alsfeld; Fiona Denham; Lucinda Tennant; W Jay Ramsey; Nicholas N Vahanian; Charles J Link
Journal:  Ochsner J       Date:  2014

10.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

Authors:  Morganna Freeman-Keller; Youngchul Kim; Heather Cronin; Allison Richards; Geoffrey Gibney; Jeffrey S Weber
Journal:  Clin Cancer Res       Date:  2015-10-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.